Related Experiment Videos
Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary
Vitalie Văcăraş1, Zoltán Zsigmond Major2, Anca Dana Buzoianu2
1Department of Neurosciences, University of Medicine and Pharmacy "Iuliu Haţieganu", Cluj-Napoca, Romania.
Aim Of The Study:
Our main purpose was to investigate if the chronic treatment with the disease-modifying drug natalizumab shows quantifiable effect on BDNF levels in multiple sclerosis patients.
Materials And Methods:
BDNF plasma concentration was evaluated using enzyme-linked immunosorbent assay in healthy individuals, not treated multiple sclerosis patients and patients treated with natalizumab.
Results:
Multiple sclerosis patients have a significantly lower amount of peripheral BDNF than healthy individuals. Patients treated with natalizumab have significantly higher BDNF levels than not treated patients.
Conclusions:
Chronic natalizumab treatment is associated with significantly increased plasma BDNF concentration in multiple sclerosis.